Aprea Therapeutics Announces Third Quarter 2026 Financial Results

Article summary

Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 clinical trial expanded to nine sites, with immunohistochemistry (IHC) testing for Cyclin E expression now in place to support biomarker assessment and future patient selection strategies $37.8 million in cash and cash equivalents as of September 30, 2026; cash runway expected into Q1 2028